Does semaglutide come from lizard venom? The real science explained

So where did the lizard venom story start?

In the 1990s, a pharmacologist named John Eng discovered that the saliva of the Gila monster, a large lizard native to the American Southwest, contained a peptide that activated the same receptor as human GLP-1. That peptide was eventually developed into exenatide, a medicine used for type 2 diabetes. Because exenatide was the first GLP-1 receptor agonist to reach patients, journalists at the time told the lizard story, and it stuck, even as the science moved on entirely.

Semaglutide came later and took a completely different route. Novo Nordisk's researchers started with the structure of human GLP-1 itself and modified it chemically: attaching a fatty-acid chain that binds to albumin in the blood, extending the molecule's half-life from minutes to roughly a week. The result is a synthetic peptide that your body's GLP-1 receptors recognise and respond to, but which no lizard has ever produced, and if you want to understand more about why semaglutide is so frequently linked to lizards despite that entirely separate origin, we cover the full story in a dedicated article. If you are curious about the broader science of how semaglutide works at a molecular level, the semaglutide overview on this site covers the mechanism in more detail.

The confusion is understandable. Both exenatide and semaglutide work on the same receptor. But sharing a target is not the same as sharing an origin, any more than two keys that fit the same lock need to have been cut by the same locksmith.

What does GLP-1 actually do, and why does it matter for weight management?

GLP-1 stands for glucagon-like peptide-1. Your small intestine releases it naturally after you eat, and it does several things at once: it tells the pancreas to release insulin in response to blood sugar, it slows the rate at which your stomach empties, and it signals to the brain that you have had enough to eat. In people with obesity, these signals are often weaker or shorter-lived than they need to be.

Semaglutide amplifies and extends that signal. Because the modified molecule stays active in the body for around seven days, a single weekly injection keeps GLP-1 receptor activity elevated continuously, rather than in the brief post-meal spike you get naturally. The practical effect, borne out in the STEP 1 trial published in the New England Journal of Medicine, was an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside a reduced-calorie diet and increased activity.

None of that mechanism depends on venom. The lizard's saliva was a clue that pointed scientists toward a receptor worth targeting. Semaglutide is the result of decades of human biochemistry research that followed that clue.

Is exenatide still used, and how does it differ from semaglutide?

Exenatide is still prescribed in the UK for type 2 diabetes, not for weight management. It is not licensed as a weight-loss medicine, and it is not dispensed under the Wegovy or Mounjaro brand names, and if you have ever wondered what the Wegovy logo looks like and how the branding helps distinguish it from other semaglutide products, we explain that on a separate page. If you come across references to the Gila monster and GLP-1 medicines in the context of weight loss, it is worth knowing the distinction clearly: exenatide has a genuine biological link to Gila monster saliva; semaglutide does not.

For anyone weighing up options for weight management in the UK, the NHS medicines page for semaglutide sets out what the medicine is, who it is licensed for, and the side effects to be aware of. It is worth reading before any consultation. You can also explore the full range of treatments available through our service if you are still working out which option fits your situation.

One thing people often tell us they felt reading about these medicines for the first time: slightly overwhelmed, and not entirely sure what to trust. That is a reasonable response to a topic that mixes legitimate science with a lot of online noise. The short answer is: the lizard story is historically interesting, but semaglutide is a precision-engineered synthetic medicine, and the evidence for it comes from large randomised trials, not folklore.

How is semaglutide prescribed for weight management in the UK?

Wegovy (semaglutide for weight management) is a prescription-only medicine. A prescriber assesses your BMI, health history, any medicines you take, and whether the treatment is appropriate for you, it is not available without that clinical step. The licensed dose schedule starts at 0.25mg weekly and is titrated over roughly 16 weeks to the 2.4mg maintenance dose, with the prescriber guiding the pace. The MHRA approved a higher 7.2mg maintenance dose in early 2026 for eligible patients with a BMI of 30 or above.

If you are considering treatment, the right starting point is a consultation with a registered prescriber rather than searching for shortcuts. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber (a real clinician, not automated software) and, if approved, treatment is dispatched the same day for free next-working-day delivery. Our clinical team can answer questions about your specific situation during the consultation process. You can also check any online pharmacy on the GPhC register before sharing any health details.

If you want to take the next step, speak to our prescribers through a free consultation and find out whether semaglutide is suitable for you.